|Videos|December 22, 2019
Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03
Author(s)Sponsored Content
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Accepts Application for Padcev Plus Keytruda For Some With Bladder Cancer
2
Verzenio Plus Endocrine Therapy Benefits Survival for Some With Breast Cancer
3
Alternative Docetaxel Dosing Reduces Toxicity Risk in Prostate Cancer
4
Improving End-of-Life Care: Making Hospice and Home Support Accessible
5
